Production (Stage)
10x Genomics, Inc.
TXG
$8.17
-$0.37-4.33%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 624.66M | 610.79M | 629.74M | 631.73M | 625.45M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 624.66M | 610.79M | 629.74M | 631.73M | 625.45M |
| Cost of Revenue | 197.65M | 196.00M | 210.13M | 222.99M | 221.31M |
| Gross Profit | 427.01M | 414.78M | 419.61M | 408.75M | 404.14M |
| SG&A Expenses | 348.30M | 343.24M | 338.33M | 339.04M | 344.71M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 806.25M | 803.24M | 806.16M | 820.06M | 832.59M |
| Operating Income | -181.59M | -192.46M | -176.42M | -188.32M | -207.14M |
| Income Before Tax | -153.40M | -177.70M | -175.92M | -233.22M | -256.91M |
| Income Tax Expenses | 3.63M | 4.93M | 6.63M | 6.56M | 7.39M |
| Earnings from Continuing Operations | -157.04 | -182.63 | -182.55 | -239.78 | -264.30 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -157.04M | -182.63M | -182.55M | -239.78M | -264.30M |
| EBIT | -181.59M | -192.46M | -176.42M | -188.32M | -207.14M |
| EBITDA | -146.88M | -156.58M | -139.57M | -151.07M | -168.92M |
| EPS Basic | -1.30 | -1.52 | -1.53 | -2.02 | -2.24 |
| Normalized Basic EPS | -0.84 | -0.91 | -0.80 | -0.88 | -0.99 |
| EPS Diluted | -1.30 | -1.52 | -1.53 | -2.02 | -2.24 |
| Normalized Diluted EPS | -0.84 | -0.91 | -0.80 | -0.88 | -0.99 |
| Average Basic Shares Outstanding | 485.00M | 481.79M | 478.76M | 475.76M | 472.40M |
| Average Diluted Shares Outstanding | 485.00M | 481.79M | 478.76M | 475.76M | 472.40M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |